FDA approves REMS-related supplement for Lynozyfic (linvoseltamab-gcpt)Jul 31Regulatory decisionlinvoseltamab-gcptRegeneron Pharmaceuticals
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Sign inSign in